RxDoctor Payments Data

Cynthia Young, MD

Family Medicine · Cary, NCNPI 1811910870

Payments from drug & device makers

$5,644in general payments, 2019–2025

Across 293 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$705
  • Amgen$578
  • Lilly USA, LLC$495
  • AstraZeneca$438
  • Preventric Diagnostics, Inc.$374
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$5,58799%
  • Education$571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,644 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,409
Medicare patients
116
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$93,326
TrulicityDulaglutide28$59,510
JardianceEmpagliflozin37$42,484
RybelsusSemaglutide15$28,974
EliquisApixaban15$21,571
MounjaroTirzepatide13$17,098
MyrbetriqMirabegron14$6,501
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,429
SynthroidLevothyroxine Sodium20$2,739
Levothyroxine Sodium129$2,344
Tramadol Hcl34$1,698
Atorvastatin Calcium124$1,469
Potassium Chloride55$1,237
Solifenacin Succinate21$1,116
Gabapentin70$1,112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,644$122,29978 claims
Lilly USA, LLCTrulicity, Mounjaro$495$76,60841 claims
Boehringer IngelheimJardiance$98$42,48437 claims
PfizerEliquis$220$21,57115 claims
AbbVieSynthroid$705$2,73920 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$23$2,344129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →